| 南娜佳.血清IGF-1和Glypican-4对慢性肾脏病非透析患者预后的早期预测价值分析[J].浙江中西医结合杂志,2024,34(10): |
| 血清IGF-1和Glypican-4对慢性肾脏病非透析患者预后的早期预测价值分析 |
|
| 投稿时间：2024-04-07 修订日期：2024-08-08 |
| DOI： |
| 中文关键词: 【关键词】慢性肾脏病 非透析 胰岛素样生长因子-1 磷脂酰肌醇蛋白聚糖-4 预后 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 385 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【】目的 分析血清胰岛素样生长因子-1(IGF-1)和磷脂酰肌醇蛋白聚糖-4(Glypican-4)对慢性肾脏病非透析患者预后的早期预测价值。方法 选择我院自2021年1月至2022年1月收治的130例慢性肾脏病非透析患者纳入观察组,对观察组患者进行随访24个月,根据预后情况,细分为预后良好组和预后不良组。另选同期的130例健康体检者纳入对照组。检测所有入选者血清IGF-1和Glypican-4表达水平,使用Kaplan-Meier法分析血清IGF-1和Glypican-4对患者预后的影响,多因素Cox回归患者预后的影响因素,受试者工作特征曲线(ROC)评价血清IGF-1联合Glypican-4对患者预后不良的预测效能。结果 观察组血清IGF-1表达水平低于对照组,Glypican-4表达水平高于对照组,差异均有统计学意义(P＜0.05)；预后不良组血清IGF-1表达水平低于预后良好组,Glypican-4表达水平高于预后良好组,差异均有统计学意义(P＜0.05)；经Kaplan-Meier法分析,低IGF-1水平组中位肾脏生存时间短于高IGF-1水平组,高Glypican-4水平组中位肾脏生存时间短于低Glypican-4水平组,差异均有统计学意义(P＜0.05)；经多因素Cox回归,低IGF-1和高Glypican-4均是慢性肾脏病非透析患者预后不良的独立影响因素(P＜0.05)；经ROC曲线分析,血清IGF-1联合Glypican-4预测慢性肾脏病非透析患者预后不良的AUC为0.928。结论 血清IGF-1和Glypican-4与慢性肾脏病非透析患者预后密切相关,低IGF-1和高Glypican-4均是患者预后不良的独立危险因素,联合应用可提高对患者预后的预测效能。 |
| 英文摘要: |
| 【】Objective To analyze the early predictive value of serum insulin-like growth factor-1 (IGF-1) and glypican-4 for prognosis of non-dialysis patients with chronic kidney disease. Methods 130 patients with chronic kidney disease without dialysis admitted to our hospital from January 2021 to January 2022 were selected as the observation group. The patients in the observation group were followed up for 24 months, and were subdivided into good prognosis group and poor prognosis group according to the prognosis. Another 130 healthy people in the same period were selected as the control group. The expression levels of serum IGF-1 and glypican-4 in all the participants were detected. The Kaplan-Meier method was used to analyze the effect of serum IGF-1 and glypican-4 on the prognosis of patients. The influencing factors of the prognosis of patients were analyzed by multivariate Cox regression. The receiver operating characteristic curve (ROC) was used to evaluate the predictive efficacy of serum IGF-1 combined with glypican-4 for poor prognosis of patients. Results The expression level of serum IGF-1 in the observation group was lower than that in the control group, and the expression level of glypican-4 was higher than that in the control group, with statistically significant differences (P<0.05). The expression level of serum IGF-1 in the poor prognosis group was lower than that in the good prognosis group, and the expression level of glypican-4 was higher than that in the good prognosis group, with statistically significant differences (P<0.05). According to the analysis of Kaplan-Meier method, the median renal survival time of the low IGF-1 level group was shorter than that of the high IGF-1 level group, and the median renal survival time of the high glypican-4 level group was shorter than that of the low glypican-4 level group, with statistically significant differences (P<0.05). Through multivariate Cox regression, low IGF-1 and high Glypican-4 were independent influencing factors for poor prognosis of non-dialysis patients with chronic kidney disease (P<0.05). Through ROC curve analysis, the AUC of serum IGF-1 combined with Glypican-4 in predicting poor prognosis of non-dialysis patients with chronic kidney disease was 0.928.Conclusion Serum IGF-1 and Glypican-4 are closely related to the prognosis of non-dialysis patients with chronic kidney disease, low IGF-1 and high Glypican-4 are independent risk factors for poor prognosis of patients, and combined application can improve the predictive efficacy of prognosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
